argenex (NASDAQ:ARGX – Get Free Report)‘s stock had its “neutral” rating reissued by investment analysts at Deutsche Bank Aktiengesellschaft in a research report issued on Friday.
Several other equities analysts have also commented on the stock. Royal Bank Of Canada increased their price objective on shares of argenex from $1,025.00 to $1,100.00 and gave the company an “outperform” rating in a research report on Tuesday, August 18th. Morgan Stanley boosted their target price on shares of argenex from $1,230.00 to $1,250.00 and gave the stock an “overweight” rating in a research report on Monday, August 31st. Weiss Ratings lowered shares of argenex from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, July 23rd. Truist Financial upped their price target on shares of argenex from $1,030.00 to $1,095.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Finally, Citigroup raised their price target on shares of argenex from $1,152.00 to $1,182.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,154.94.
Read Our Latest Report on argenex
argenex Price Performance
argenex (NASDAQ:ARGX – Get Free Report) last issued its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, topping the consensus estimate of $5.86 by $1.46. argenex had a return on equity of 43.59% and a net margin of 32.19%. The business had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.45 billion. As a group, equities research analysts expect that argenex will post 28.83 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the company. Tidal Investments LLC lifted its holdings in shares of argenex by 97.8% during the second quarter. Tidal Investments LLC now owns 2,362 shares of the company’s stock worth $2,191,000 after purchasing an additional 1,168 shares during the period. Peregrine Capital Management LLC purchased a new stake in argenex in the second quarter valued at approximately $27,584,000. Squarepoint Ops LLC increased its holdings in argenex by 314.8% in the 2nd quarter. Squarepoint Ops LLC now owns 58,400 shares of the company’s stock worth $54,182,000 after buying an additional 44,321 shares during the period. Optiver Holding B.V. increased its holdings in argenex by 907.0% in the 1st quarter. Optiver Holding B.V. now owns 10,110 shares of the company’s stock worth $7,383,000 after buying an additional 9,106 shares during the period. Finally, Janus Henderson Group PLC increased its holdings in argenex by 3.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock worth $1,847,592,000 after buying an additional 83,568 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.
argenex Company Profile
argenx SE (NASDAQ:ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company combines antibody engineering technologies with disease biology to discover medicines that target the underlying mechanisms of immune-mediated disorders.
argenx’s leading product is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo in the United States. The therapies are designed to reduce disease-causing immunoglobulin G (IgG) antibodies by targeting the neonatal Fc receptor (FcRn).
See Also
- Five stocks we like better than argenex
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
